Bill Text: IL HB0601 | 2021-2022 | 102nd General Assembly | Introduced
NOTE: There are more recent revisions of this legislation. Read Latest Draft
Bill Title: Amends the Criminal Code of 2012. Provides that commission of possession of burglary tools includes when a person, knowingly and with the intent to enter the motor vehicle and with the intent to commit therein a felony or theft, possesses a device designed to: (1) unlock or start a motor vehicle without the use or possession of the key to the motor vehicle; or (2) capture or duplicate a signal from the key fob of a motor vehicle to unlock or start the motor vehicle without the use or possession of the key to the motor vehicle.
Spectrum: Moderate Partisan Bill (Democrat 31-8)
Status: (Passed) 2022-05-26 - Public Act . . . . . . . . . 102-0903 [HB0601 Detail]
Download: Illinois-2021-HB0601-Introduced.html
Bill Title: Amends the Criminal Code of 2012. Provides that commission of possession of burglary tools includes when a person, knowingly and with the intent to enter the motor vehicle and with the intent to commit therein a felony or theft, possesses a device designed to: (1) unlock or start a motor vehicle without the use or possession of the key to the motor vehicle; or (2) capture or duplicate a signal from the key fob of a motor vehicle to unlock or start the motor vehicle without the use or possession of the key to the motor vehicle.
Spectrum: Moderate Partisan Bill (Democrat 31-8)
Status: (Passed) 2022-05-26 - Public Act . . . . . . . . . 102-0903 [HB0601 Detail]
Download: Illinois-2021-HB0601-Introduced.html
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
| ||||||||||||||||||||
1 | AN ACT concerning criminal law.
| |||||||||||||||||||
2 | Be it enacted by the People of the State of Illinois,
| |||||||||||||||||||
3 | represented in the General Assembly:
| |||||||||||||||||||
4 | Section 5. The Illinois Controlled Substances Act is | |||||||||||||||||||
5 | amended by changing Section 316 as follows:
| |||||||||||||||||||
6 | (720 ILCS 570/316)
| |||||||||||||||||||
7 | Sec. 316. Prescription Monitoring Program. | |||||||||||||||||||
8 | (a) The Department must provide for a
Prescription | |||||||||||||||||||
9 | Monitoring Program for Schedule II, III, IV, and V controlled | |||||||||||||||||||
10 | substances that includes the following components and | |||||||||||||||||||
11 | requirements:
| |||||||||||||||||||
12 | (1) The
dispenser must transmit to the
central | |||||||||||||||||||
13 | repository, in a form and manner specified by the | |||||||||||||||||||
14 | Department, the following information:
| |||||||||||||||||||
15 | (A) The recipient's name and address.
| |||||||||||||||||||
16 | (B) The recipient's date of birth and gender.
| |||||||||||||||||||
17 | (C) The national drug code number of the | |||||||||||||||||||
18 | controlled
substance
dispensed.
| |||||||||||||||||||
19 | (D) The date the controlled substance is | |||||||||||||||||||
20 | dispensed.
| |||||||||||||||||||
21 | (E) The quantity of the controlled substance | |||||||||||||||||||
22 | dispensed and days supply.
| |||||||||||||||||||
23 | (F) The dispenser's United States Drug Enforcement |
| |||||||
| |||||||
1 | Administration
registration number.
| ||||||
2 | (G) The prescriber's United States Drug | ||||||
3 | Enforcement Administration
registration number.
| ||||||
4 | (H) The dates the controlled substance | ||||||
5 | prescription is filled. | ||||||
6 | (I) The payment type used to purchase the | ||||||
7 | controlled substance (i.e. Medicaid, cash, third party | ||||||
8 | insurance). | ||||||
9 | (J) The patient location code (i.e. home, nursing | ||||||
10 | home, outpatient, etc.) for the controlled substances | ||||||
11 | other than those filled at a retail pharmacy. | ||||||
12 | (K) Any additional information that may be | ||||||
13 | required by the department by administrative rule, | ||||||
14 | including but not limited to information required for | ||||||
15 | compliance with the criteria for electronic reporting | ||||||
16 | of the American Society for Automation and Pharmacy or | ||||||
17 | its successor. | ||||||
18 | (2) The information required to be transmitted under | ||||||
19 | this Section must be
transmitted not later than the end of | ||||||
20 | the next business day after the date on which a
controlled | ||||||
21 | substance is dispensed, or at such other time as may be | ||||||
22 | required by the Department by administrative rule.
| ||||||
23 | (3) A dispenser must transmit the information required | ||||||
24 | under this Section
by:
| ||||||
25 | (A) an electronic device compatible with the | ||||||
26 | receiving device of the
central repository;
|
| |||||||
| |||||||
1 | (B) a computer diskette;
| ||||||
2 | (C) a magnetic tape; or
| ||||||
3 | (D) a pharmacy universal claim form or Pharmacy | ||||||
4 | Inventory Control form.
| ||||||
5 | (3.5) The requirements of paragraphs (1), (2), and (3) | ||||||
6 | of this subsection (a) also apply to opioid treatment | ||||||
7 | programs that prescribe Schedule II, III, IV, or V | ||||||
8 | controlled substances for the treatment of opioid use | ||||||
9 | disorder. | ||||||
10 | (4) The Department may impose a civil fine of up to | ||||||
11 | $100 per day for willful failure to report controlled | ||||||
12 | substance dispensing to the Prescription Monitoring | ||||||
13 | Program. The fine shall be calculated on no more than the | ||||||
14 | number of days from the time the report was required to be | ||||||
15 | made until the time the problem was resolved, and shall be | ||||||
16 | payable to the Prescription Monitoring Program.
| ||||||
17 | (a-5) Notwithstanding subsection (a), a licensed | ||||||
18 | veterinarian is exempt from the reporting requirements of this | ||||||
19 | Section. If a person who is presenting an animal for treatment | ||||||
20 | is suspected of fraudulently obtaining any controlled | ||||||
21 | substance or prescription for a controlled substance, the | ||||||
22 | licensed veterinarian shall report that information to the | ||||||
23 | local law enforcement agency. | ||||||
24 | (b) The Department, by rule, may include in the | ||||||
25 | Prescription Monitoring Program certain other select drugs | ||||||
26 | that are not included in Schedule II, III, IV, or V. The |
| |||||||
| |||||||
1 | Prescription Monitoring Program does not apply to
controlled | ||||||
2 | substance prescriptions as exempted under Section
313.
| ||||||
3 | (c) The collection of data on select drugs and scheduled | ||||||
4 | substances by the Prescription Monitoring Program may be used | ||||||
5 | as a tool for addressing oversight requirements of long-term | ||||||
6 | care institutions as set forth by Public Act 96-1372. | ||||||
7 | Long-term care pharmacies shall transmit patient medication | ||||||
8 | profiles to the Prescription Monitoring Program monthly or | ||||||
9 | more frequently as established by administrative rule. | ||||||
10 | (d) The Department of Human Services shall appoint a | ||||||
11 | full-time Clinical Director of the Prescription Monitoring | ||||||
12 | Program. | ||||||
13 | (e) (Blank). | ||||||
14 | (f) Within one year of January 1, 2018 (the effective date | ||||||
15 | of Public Act 100-564), the Department shall adopt rules | ||||||
16 | requiring all Electronic Health Records Systems to interface | ||||||
17 | with the Prescription Monitoring Program application program | ||||||
18 | on or before January 1, 2021 to ensure that all providers have | ||||||
19 | access to specific patient records during the treatment of | ||||||
20 | their patients. These rules shall also address the electronic | ||||||
21 | integration of pharmacy records with the Prescription | ||||||
22 | Monitoring Program to allow for faster transmission of the | ||||||
23 | information required under this Section. The Department shall | ||||||
24 | establish actions to be taken if a prescriber's Electronic | ||||||
25 | Health Records System does not effectively interface with the | ||||||
26 | Prescription Monitoring Program within the required timeline. |
| |||||||
| |||||||
1 | (g) The Department, in consultation with the Advisory | ||||||
2 | Committee, shall adopt rules allowing licensed prescribers or | ||||||
3 | pharmacists who have registered to access the Prescription | ||||||
4 | Monitoring Program to authorize a licensed or non-licensed | ||||||
5 | designee employed in that licensed prescriber's office or a | ||||||
6 | licensed designee in a licensed pharmacist's pharmacy who has | ||||||
7 | received training in the federal Health Insurance Portability | ||||||
8 | and Accountability Act to consult the Prescription Monitoring | ||||||
9 | Program on their behalf. The rules shall include reasonable | ||||||
10 | parameters concerning a practitioner's authority to authorize | ||||||
11 | a designee, and the eligibility of a person to be selected as a | ||||||
12 | designee. In this subsection (g), "pharmacist" shall include a | ||||||
13 | clinical pharmacist employed by and designated by a Medicaid | ||||||
14 | Managed Care Organization providing services under Article V | ||||||
15 | of the Illinois Public Aid Code under a contract with the | ||||||
16 | Department of Healthcare and Family Services for the sole | ||||||
17 | purpose of clinical review of services provided to persons | ||||||
18 | covered by the entity under the contract to determine | ||||||
19 | compliance with subsections (a) and (b) of Section 314.5 of | ||||||
20 | this Act. A managed care entity pharmacist shall notify | ||||||
21 | prescribers of review activities. | ||||||
22 | (Source: P.A. 100-564, eff. 1-1-18; 100-861, eff. 8-14-18; | ||||||
23 | 100-1005, eff. 8-21-18; 100-1093, eff. 8-26-18; 101-81, eff. | ||||||
24 | 7-12-19; 101-414, eff. 8-16-19.)
|